OD-07656 / Odyssey Therap - LARVOL DELTA

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P2 | N=57 | Recruiting | Sponsor: Odyssey Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P2 | N=57 | Not yet recruiting | Sponsor: Odyssey Therapeutics

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=101 | Completed | Sponsor: Odyssey Therapeutics | Recruiting ➔ Completed | N=156 ➔ 101 | Trial completion date: Oct 2025 ➔ Nov 2024 | Trial primary completion date: May 2025 ➔ Nov 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis

Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor, OD-07656, at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024 (Businesswire) - "Odyssey Therapeutics, Inc...announced that new translational data for its receptor-interacting protein kinase 2 (RIPK2) scaffolding inhibitor product candidate, OD-07656, will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held October 25-30, 2024. Activation of RIPK2 in innate immune cells is linked to multiple aspects of inflammatory bowel disease (IBD) pathogenesis through its role as a signal transducer and amplifier of cytokine production."

Clinical data • Immunology • Inflammatory Bowel Disease

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=156 | Recruiting | Sponsor: Odyssey Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=156 | Not yet recruiting | Sponsor: Odyssey Therapeutics

New P1 trial • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis